MOG and myeloid sarcoma: A case in point is the prevalence of MOG autoantibodies among patients with demyelinating disorders, such as MS and optic neuritis, which is estimated between 0.3–5%, compared with a prevalence of 0–1.3% among healthy individuals (17–22).